Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD80/CD86 costimulation regulates acute vascular rejection.

Karoline A Hosiawa1, Hao Wang, Mark E DeVries

  • 1Division of Experimental Therapeutics, University Health Network, Toronto General Research Institute, Toronto General Hospital, Toronto, Ontario, Canada.

Journal of Immunology (Baltimore, Md. : 1950)
|October 21, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clock-like behavior across Orthoebolavirus species suggests alternative evolution of the 2026 Bundibugyo virus outbreak.

Journal of infection in developing countries·2026
Same author

FreeTune4D: Anatomy-Aware 4D-MRI Motion Reconstruction Benchmark and Free Fine-Tuning Framework.

IEEE journal of biomedical and health informatics·2026
Same author

Case presentation of patients hospitalised with mpox (subclade Ib/2023sh) including children, adolescents, and adults in South Kivu, Democratic Republic of the Congo: an observational cohort study.

The Lancet. Infectious diseases·2026
Same author

Deciphering the etiology of the 2024 outbreak of undiagnosed febrile illness in Panzi, Democratic Republic of the Congo.

Nature medicine·2026
Same author

Automatic lung dose painting for functional lung avoidance radiotherapy through multi-modality-guided dose prediction.

Physics in medicine and biology·2025
Same author

Novel synthetic strategy for aromatic ether coumarin derivatives and evaluation of anti-allergic potential.

BMC chemistry·2025

Blocking CD86 costimulatory molecules overcomes acute vascular rejection (AVR) in xenotransplantation. Combining CD86 blockade with cyclosporin A (CsA) therapy enables indefinite xenograft survival by inhibiting AVR and cell-mediated rejection (CMR).

Area of Science:

  • Immunology
  • Transplantation Biology
  • Molecular Medicine

Background:

  • Xenotransplantation offers a solution to human organ donor shortages.
  • Acute vascular rejection (AVR) remains a significant barrier, unaddressed by standard immunosuppressants.
  • CD80/CD86 costimulatory molecules are critical in immune responses and transplant rejection.

Purpose of the Study:

  • To investigate the role of CD80 and CD86 costimulatory molecules in regulating acute vascular rejection (AVR) during xenotransplantation.
  • To determine if targeting CD80/CD86 pathways can prevent xenograft rejection and prolong survival.

Main Methods:

  • Lewis rat hearts were heterotopically transplanted into wild-type or CD80/CD86-deficient C57BL/6 mice.
  • Recipients were treated with CD80 or CD86 neutralizing antibodies, with or without cyclosporin A (CsA).

Related Experiment Videos

  • Rejection pathologies and survival times were monitored post-transplantation.

    • Main Results:

    • CD80 blockade or deficiency led to rapid rejection (POD 5-6) with AVR pathology.
    • CD86 blockade or deficiency resulted in delayed rejection (POD 17) with cell-mediated rejection (CMR) pathology.
    • CD86 blockade, but not CD80 blockade, sensitized recipients to CsA, achieving indefinite xenograft survival.

    Conclusions:

    • CD80 and CD86 have opposing roles: CD80 promotes cell-mediated rejection (CMR), while CD86 drives acute vascular rejection (AVR).
    • Blocking the CD86 costimulatory pathway effectively overcomes AVR in xenotransplantation.
    • Combining CD86 neutralization with CsA therapy provides a strategy for indefinite xenograft survival by inhibiting both AVR and CMR.